Kenvue Inc.’s early months as a standalone company, after Johnson & Johnson sold its controlling stake, haven’t meant it’s standing alone in the consumer health segment and isn’t working with competitors to expand its business.
Kenvue Marks Independence By Extending Motrin And Tylenol Lines With Help From A Competitor
Kenvue also not standing apart from competitors concerning headwinds from foreign exchange rates, a slow start to the cough/cold season and looking ahead to FDA decision on oral phenylephrine, it reports with its third-quarter results.
More from Earnings
• By
Coty Inc. reports fiscal second quarter sales slipped 3% on a reported basis to $1.67bn, reflecting further slowing of the mass beauty market, particularly color cosmetics.
• By
L’Oréal Groupe expects total sales in 2025 to beat 4%-4.5% growth anticipated for the overall beauty market, with US population growth, planned innovations boding well across its beauty businesses.
• By
Cincinnati-based P&G reports its antiperspirants/deodorants business is a ‘pocket of strength,’ growing 11% in the US in the fiscal second quarter and helping lift overall beauty sales as skin care stumbles.
New York-based International Flavors & Fragrances, Inc.’s Scent division is undertaking R&D in natural, synthetic chemistry and biotech molecules, says CEO Erik Fyrwald during a third quarter earnings presentation 6 November.
More from Business
• By
Target’s Beauty division was its strongest business unit in fiscal 2024, nearly doubling in six years to reach $13.2bn on strong in-store presentation and digital support, the retailer says.
• By
Estee Lauder Companies collaborates with Serpin Pharma to explore anti-inflammatory innovation and skin longevity, while L’Oréal Group celebrates the grand opening of North America Research & Innovation Center with ribbon cutting event.
• By
K-beauty (Korean beauty)’s success in US e-commerce in 2024 was independent of overall US market beauty growth, surging 63% year-over-year on average, according to Samsung Securities.